small nucleolar RNA, C/D box 126Genealiases: MIR1201 · MIRN1201
Q-omics provides the consensus-scored SNORD126 profile across patient tissues and cancer cell-line models. SNORD126 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, SNORD126 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, SNORD126 RNA expression shows 7,468 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight OV, LUSC, and LSCC as cancer lineages where SNORD126 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD126 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD126 survival associations across molecular data types. SNORD126 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD126 RNA expression–survival associations across cancer types. High SNORD126 expression shows unfavorable associations in OV, KIRP, BRCA, ACC, KIRC and ESCA. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for SNORD126 RNA expression.
This table summarizes SNORD126 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD126. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD126 shows lower tumor expression in KIRC and higher tumor expression in LUSC and LUAD. The LUSC box plot shows higher SNORD126 RNA expression in tumor versus normal tissue (log2 FC = +0.307, t-test p = .005).
This table shows molecular features associated with SNORD126 in patient tissues and cancer cell lines. In patient samples, SNORD126 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
